FH1
Based on 1 Customer Validation
FH1 (NSC 12407) is a NQO2 inhibitor with hepatoprotective effects. FH1 enhances hepatocyte function and promotes differentiation of induced pluripotent stem (iPS)-derived hepatocytes to a more mature phenotype and maturation of well-differentiated hepatocyte-like cell (iHeps) cultures. FH1 protects against Acetaminophen (HY-66005)-induced hepatotoxicity in both embryos and adult zebrafish.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.17%
- CAS 番号: 2719-05-3
- 分子式: C17H18N2O2
- 分子量:282.34
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
FH1 (NSC 12407, 5 μg/mL, 0-40 days) enhances hepatic maturation and maintain the hepatic differentiation state of hiPSC-HLCs[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:hiPSC-HLCs in the differentiated hepatic state.
-
Concentration:5 µg/mL.
-
Incubation Time:0-40 days.
-
Result:Kept more than 50% hiPSC-HLCs to produce the four factors till day 40.
Can help hiPSC-HLCs to maintain a relatively mature hepatic differentiation state for about 40 days.
Maintained a higher level of hALB in the supernatant than that in controls.
Maintained relatively high mRNA levels of hNTCP, hRXR, hHNF4α, and hALB for over functional small molecule FH1 can help hiPSC-HLCs to maintain a relatively mature hepatic differentiation state for about 40 days.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 2719-05-3
-
性状 Solid
-
分子量 282.34
-
分子式 C17H18N2O2
-
Color Yellow to orange
-
SMILES
CC(NC1=CC=C(CC2=CC=C(NC(C)=O)C=C2)C=C1)=O
-
別名
NSC 12407; BRD-K4477
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
溶剤 & 溶解度
DMSO : 13 mg/mL (46.04 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.85 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.85 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (271 KB)
-
SDS (399 KB)
- English - EN (399 KB)
- Français - FR (399 KB)
- Deutsch - DE (399 KB)
- Norwegian - NO (399 KB)
- Español - ES (399 KB)
- Swedish - SV (399 KB)
- Italian - IT (399 KB)
- Korean - KR (399 KB)
- Portuguese - PT (399 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Schepers AG, et al. Identification of NQO2 As a Protein Target in Small Molecule Modulation of Hepatocellular Function. ACS Chem Biol. 2021 Sep 17;16(9):1770-1778. [Content Brief]
[2]. Shan J, et al. Identification of small molecules for human hepatocyte expansion and iPS differentiation. Nat Chem Biol. 2013 Aug;9(8):514-20. [Content Brief]
[3]. Lunzhi Yuan, et al. A Chimeric Humanized Mouse Model by Engrafting the Human Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cell for the Chronic Hepatitis B Virus Infection. Front Microbiol. 2018 May 8;9:908. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5418 mL | 17.7091 mL | 35.4183 mL | 88.5457 mL |
| 5 mM | 0.7084 mL | 3.5418 mL | 7.0837 mL | 17.7091 mL | |
| 10 mM | 0.3542 mL | 1.7709 mL | 3.5418 mL | 8.8546 mL | |
| 15 mM | 0.2361 mL | 1.1806 mL | 2.3612 mL | 5.9030 mL | |
| 20 mM | 0.1771 mL | 0.8855 mL | 1.7709 mL | 4.4273 mL | |
| 25 mM | 0.1417 mL | 0.7084 mL | 1.4167 mL | 3.5418 mL | |
| 30 mM | 0.1181 mL | 0.5903 mL | 1.1806 mL | 2.9515 mL | |
| 40 mM | 0.0885 mL | 0.4427 mL | 0.8855 mL | 2.2136 mL |
FH1 関連分類
HY-12346 関連分類
Powered by Bioz